Overview

Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck

Status:
Terminated

Trial end date:
2021-06-01

Target enrollment:

Participant gender:

Summary

This is an open-label, non-randomized, two arm, Phase I research study of superselective intraarterial Cetuximab (Erbitux) with or without radiation therapy for treatment of recurrent unresectable squamous cell carcinoma of the head and neck (HNSCC).

Phase:

Phase 1

Details

Lead Sponsor:

Northwell Health

Treatments:

Cetuximab